| Paul R Dunn, AA | |
|
111 Colchester Ave, Burlington, VT 05401-1473 | |
| (802) 847-0000 | |
| Not Available |
| Full Name | Paul R Dunn |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 12 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396089553 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | 135-0000023 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Central Vermont Medical Center | Barre, VT | Hospital |
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
| Entity Name | Central Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831374362 PECOS PAC ID: 9335138817 Enrollment ID: O20040510001034 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123241 PECOS PAC ID: 3779491071 Enrollment ID: O20060822000040 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
| Entity Name | Southwestern Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205865789 PECOS PAC ID: 0143138446 Enrollment ID: O20060929000045 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul R Dunn, AA 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 | Paul R Dunn, AA 111 Colchester Ave, Burlington, VT 05401-1473 Ph: (802) 847-0000 |
News Archive
Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.
Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.
The first expert consensus on ventricular arrhythmias is published today. The novel document compiles current evidence on the diagnosis and management of ventricular arrhythmias and was agreed by international experts from three continents.
Taller men are able to earn more money than their shorter counterparts simply because taller people are perceived to be more intelligent and powerful, this according to a study published in The Economic Record by Wiley-Blackwell.
BioCryst Pharmaceuticals, Inc. announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility.
› Verified 7 days ago
Mr. Matthew Peter Fazio, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave., Uvm Mc - Anesthesiology, Burlington, VT 05401 Phone: 802-847-2415 Fax: 802-847-5324 | |
Mr. Jay Benjamin Ginns, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2415 | |
Aldijana Mekic, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Ms. Caroline V. Horn, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave., Uvm Medical Center, Dept. Of Anesthesiology, Burlington, VT 05401 Phone: 802-847-2415 Fax: 802-847-5324 | |
Mr. Nathan Horn, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2727 Fax: 802-847-4817 | |
Stacey A Mckenna, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-2415 Fax: 802-847-5324 |